Cancer Risks pp 181-189 | Cite as

Strategies in the Prevention of Infections by Oncogenic Viruses

  • F. Deinhardt
Conference paper

Abstract

Viruses of various families of the RNA or the DNA viruses are associated with tumors in both animals and man. The mechanisms by which such oncogenic viruses transform normal cells into malignant cells differ. However, they all produce genetic changes and/or changes in the expression of genes which are responsible for controlling normal or abnormal cellular functions. Simply put, a strategy to prevent infection with oncogenic viruses (or rather, to prevent the oncogenic result of such infection) would be to interfere with viral replication, by inhibiting integration of the viral genome into the host-cell genome, or by suppression of viral gene expression, each of which can lead to genetic alteration in host cells. Inhibition of viral replication, at least in some experimental systems, has been achieved by blocking viral enzymes through providing synthetic small substrate decoys in large excess. Blocking the reverse transcriptase of retroviruses with various chemical substances also has been tried in many studies. However, although chemicals which preferentially block viral reverse transcriptases and not host-cell enzymes have been identified, their therapeutic efficiency has been disappointing. This is because they only inhibit virus multiplication but do not eliminate the already integrated viral genomes. Also, such chemicals would have to be given for a long time, possibly even lifelong, which is impracticable and in most cases impossible because of toxicity.

Keywords

Sugar Toxicity Hepatitis Hydrate Europe 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bassendine MF (1986) Alcohol — a major risk factor for hepatocellular carcinoma? J Hepatol 2:513–519PubMedCrossRefGoogle Scholar
  2. Beasley RP, Hwang LY (1984) Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds) Viral hepatitis and liver disease. Grune and Stratton, Orlando, pp 209–224Google Scholar
  3. Beasley RP, Hwang LY, Lee GGY, Lan CC, Roan CH, Huang FY (1983) Prevention of perinatally transmitted hepatitis B virus infection with hepatitis B vaccine. Lancet 2:1099–1102PubMedCrossRefGoogle Scholar
  4. Biggin M, Farrell PJ, Barrell BG (1984) Transcription and DNA sequence of the Bam HI L fragment of B95-8 Epstein-Barr virus. EMBO J 3:1083–1090PubMedGoogle Scholar
  5. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P (1980) Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 286:533–535PubMedCrossRefGoogle Scholar
  6. Chakraborty PR, Ruiz-Opazo N, Shouval D, Shafritz DA (1980) Identification of integrated hepatitis B virus DNA and expression of viral RNA in an HBsAg-producing human hepatocellular carcinoma cell line. Nature 286:531–533PubMedCrossRefGoogle Scholar
  7. Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P, Weiss R (1986) What to call the AIDS virus? Nature 321:10PubMedGoogle Scholar
  8. Deinhardt F, Gust ID (1982) Viral hepatitis. Bull WHO 60:661–691PubMedGoogle Scholar
  9. Deinhardt F, Zuckerman AJ (1985) Immunization against hepatitis B: report on a WHO meeting on viral hepatitis in Europe. J Med Virol 17:209–217PubMedCrossRefGoogle Scholar
  10. Dunk AA, Ikeda T, Pignatelli M, Thomas HC (1986) Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 2:419–429PubMedCrossRefGoogle Scholar
  11. Edman JC, Gray P, Valenzuela P, Rall LB, Rutter WJ (1980) Integration of hepatitis B virus sequences and their expression in a human hepatoma cell. Nature 286:535–538PubMedCrossRefGoogle Scholar
  12. Epstein MA (1986) Vaccination against Epstein-Barr virus: current progress and future strategies. Lancet 1:1425–1427PubMedCrossRefGoogle Scholar
  13. Fowler MJF, Greenfield C, Chu CM, Karayiannis P, Dunk A, Lok ASF, Lai CL, Yeoh EK, Monjardino JP, Wankya BM, Thomas HC (1986) Integration of HBV-DNA may not be a prerequisite for the maintenance of the state of malignant transformation. Hepatol 2:218–229CrossRefGoogle Scholar
  14. Gerber MA, Thung SN (1985) Biology of disease. Molecular and cellular pathology of hepatitis B. Lab Invest 52:572–590PubMedGoogle Scholar
  15. Goudeau A, Lo KJ, Coursaget P, Tong MJ, Yeh CL, Tsai YT, Lee JK, Wu TC, Yeh SH, Lee SD (1983) Prevention of hepatitis B virus infection in children born to HBsAg positive/HBeAg positive mothers. Preliminary results of active and passive-active immunization. Dev Biol Stand 54:399–404PubMedGoogle Scholar
  16. Heermann KH, Goldmann U, Schwartz W, Seyfarth T, Baumgarten H, Gerlich WH (1984) Large surface proteins of hepatitis B virus containing the pre-S sequence. J Virol 52:396–402PubMedGoogle Scholar
  17. Hilleman MR (1985) Newer directions in vaccine development and utilization. J Inf Dis 151:407–419CrossRefGoogle Scholar
  18. Hilleman MR, Bertland AU, Buynak EB, Lampson GP, McAleer WJ, McLean AA, Roehm RR, Tytell AA (1978) Clinical and laboratory studies of HBsAg vaccine. In: Vyas GN, Cohen SN, Schmid R (eds) Viral hepatitis. Franklin Institute, Philadelphia, pp 525–538Google Scholar
  19. Hilleman MR, Bynak EB, Markus HZ, Maigetter RZ, McAleer WJ, McLean AA, Miller WJ, Wampler DE, Weibel RE (1984) Control of hepatitis B virus infection: vaccines produced from Alexander cell line and from recombinant yeast cell cultures. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds) Viral hepatitis and liver disease. Grune and Stratton, Orlando, pp 307–314Google Scholar
  20. Hummel M, Thorley-Lawson DA, Kieff E (1984) An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp 220/200). J Virol 49:413–417PubMedGoogle Scholar
  21. Infectious Diseases Society (1986) Acquired immunodeficiency syndrome. J Inf Dis 154:1–9CrossRefGoogle Scholar
  22. Jameel S, Siddiqui A (1986) The human hepatitis B virus enhancer requires trans-acting cellular factor(s) for activity. Mol Cell Biol 6:710–715PubMedGoogle Scholar
  23. Kanai K, Takehiro A, Noto H, Nishida M, Takahashi K, Kawashima Y, Igarashi Y, Matsushita K, Shimizu M (1985) Prevention of perinatal transmission of hepatitis B virus (HBV) to children of e antigen-positive HBV carrier mothers by hepatitis B immune globulin and HBV vaccine. J Inf Dis 151:287–290CrossRefGoogle Scholar
  24. Klein G (ed) (1980) Viral oncology. Raven, New YorkGoogle Scholar
  25. Klinkert MQ, Theilmann L, Pfaff E, Schaller H (1986) Pre-S1 antigens and antibodies early in the course of acute hepatitis B virus infection. J Virol 58:522–525PubMedGoogle Scholar
  26. Lo KJ, Tsai YT, Lee SD, Wu TC, Wang JW, Chen GH, Yeh CL, Chiang BN, Yeh SH, Goudeau A, Coursaget P, Tong MJ (1985) Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Inf Dis 152:817–822CrossRefGoogle Scholar
  27. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307:178–180PubMedCrossRefGoogle Scholar
  28. Milich DR, Thornton GB, Neurath AR, Kent SB, Michel ML, Tiollais P, Chisari FV (1985) Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228:1195–1199PubMedCrossRefGoogle Scholar
  29. Morgan AJ, Smith AR, Barker RN, Epstein MA (1984) A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, pg 340. J Gen Virol 65:397–404PubMedCrossRefGoogle Scholar
  30. Moss B, Smith GL, Gerin JL, Purcell RH (1984) Use of vaccinia virus as a vector for the construction of live recombinant hepatitis B virus vaccines. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds) Viral hepatitis and liver disease. Grune and Stratton, Orlando, pp 293–306Google Scholar
  31. Nethersell A, Sikora K (1985) Interferons and malignant disease. In: Taylor-Papadimitriou J (ed) Interferons. Their impact in biology and medicine. Oxford University Press, Oxford, pp 127–145Google Scholar
  32. Neurath AR, Kent SBH, Strick N, Taylor P, Stevens CE (1985) Hepatitis B virus contains pre-S gene-encoded domains. Nature 315:154–156PubMedCrossRefGoogle Scholar
  33. Newman MJ, Baker IT, Reitz MS, Eiden M, Blattner WA, Gallo RC, Manns DL (1986) Serological characterization of human T-cell leukemia (lymphotropic) virus, type I (HTLV-I) small envelope protein. Virology 150:106–116PubMedCrossRefGoogle Scholar
  34. Offensperger W, Wahl S, Neurath AR, Price P, Strick N, Kent SBH, Christman JK, Acs G (1985) Expression in Escherichia coli of a cloned DNA sequence encoding the pre-S region of hepatitis B virus. Proc Natl Acad Sci USA 82:7540–7544PubMedCrossRefGoogle Scholar
  35. Purcell RH, Gerin JL (1985) Prospects for second and third generation hepatitis B vaccines. Hepatology 5:159–163PubMedCrossRefGoogle Scholar
  36. Rasheed S, Norman GL, Gill PS, Meyer PR, Cheng L, Levine AM (1986) Virus-neutralizing activity, serologic heterogeneity, and retrovirus isolation from homosexual men in the Los Angeles area. Virology 1500:1–9CrossRefGoogle Scholar
  37. Robinson WS, Miller RH, Klote L, Marion PL, Lee SC 61984) Hepatitis B virus and hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds) Viral hepatitis and liver disease. Grune and Stratton, Orlando, pp 245–263Google Scholar
  38. Sarma PS, Gruber J (1986) Meeting highlights. Vaccination approaches for retrovirus infection. JNCI 76:769–777Google Scholar
  39. Scolnick EM, McLean AA, West DJ, Dienstag JL, Watkins E, Deinhardt F, Jilg W (1984) Antibody and clinical responses among healthy adults to a hepatitis B vaccine made by recombinant DNA. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds) Viral hepatitis and liver disease. Grune and Stratton, Orlando, pp 315–317Google Scholar
  40. Seeger C, Ganem D, Varmus HE (1986) Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 232:477–484PubMedCrossRefGoogle Scholar
  41. Starcich, Hahn BH, Shaw GM, McNeely PD, Modrow S, Wolf H, Parks ES, Parks WP, Josephs SF, Gallo RC, Wong-Staal F (1986) Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45:637–648PubMedCrossRefGoogle Scholar
  42. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN (1984) Hepatitis B vaccine: an overview. In: Vyas GN, Dienstag JL, Hoofnagle JH (eds) Viral hepatitis and liver disease. Grune and Stratton, Orlando, pp 275–291Google Scholar
  43. WHO Collaborating Centres on AIDS: Memorandum from a WHO meeting (1986). Bull WHO 64:37–46Google Scholar
  44. Zachoval R, Jilg W, Lorbeer B, Schmidt M, Deinhardt F (1984) Passive/active immunization against hepatitis B. J Inf Dis 150:112–117CrossRefGoogle Scholar
  45. Zanetti AR, Dentico P, Del Vecchio Blanco C, Sagnelli E, Villa E, Ferroni P, Bergamini F (1986) Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B. Final report. J Med Virol 18:327–334PubMedCrossRefGoogle Scholar
  46. Zuckermann AJ (1985) New hepatitis B vaccines. Br Med J 290:492–496CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • F. Deinhardt

There are no affiliations available

Personalised recommendations